Roginolisib + Ruxolitinib combination

Current understanding

To be populated as evidence accumulates.

2026-05-19 — TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea: cross-connection with tgr-1202-pi3k-delta-inhibitor-mpn: Parallel PI3Kδ + ruxolitinib combinations testing the dual JAK-STAT + PI3K-AKT blockade rationale in MPNs. (novelty: 3)
2026-03-30 — A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers: cross-connection with ioa-244-pi3kd-inhibitor-mpn: Both IOA-244 and roginolisib are selective PI3Kδ inhibitors being combined with ruxolitinib in myelofibrosis — converging mechanistic rationale of dual PI3Kδ + JAK1/2 blockade, suggesting a class-level therapeutic hypothesis in MF. (novelty: 4)
2026-04-27 — A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors: Trial-early: Early-phase clinical trial launched to assess safety and tolerability of roginolisib (PI3K-delta inhibitor) added to ruxolitinib in myelofibrosis patients unresponsive to JAK inhibitor therapy; efficacy endpoints not yet reported. (novelty: 4)